{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:58:55Z","timestamp":1790611135824,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03550-2","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:39:08Z","timestamp":1784536748000},"page":"4718-4729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase\u00a0Inhibitors for Alopecia Areata"],"prefix":"10.1007","volume":"43","author":[{"given":"James Q.","family":"Del Rosso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pariser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7448-7809","authenticated-orcid":false,"given":"Neal","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Deering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Harshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Barghout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"3550_CR1","unstructured":"LEQSELVI\u2122 (deuruxolitinib) tablets. Full Prescribing Information. Whippany, NJ: Sun Pharmaceutical Industries, Inc.; 2024."},{"key":"3550_CR2","unstructured":"Olumiant\u00ae (baricitinib). Full Prescribing Information. Indianapolis, IN: Eli Lilly and Company; 2022."},{"key":"3550_CR3","unstructured":"Litfulo\u00ae (ritlecitinib). Full Prescribing Information. New York, NY: Pfizer, Inc.; 2023."},{"key":"3550_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jaut.2018.12.001","volume":"98","author":"T Simakou","year":"2019","unstructured":"Simakou T, Butcher JP, Reid S, Henriquez FL. Alopecia areata: a multifactorial autoimmune condition. J Autoimmun. 2019;98:74\u201385.","journal-title":"J Autoimmun"},{"issue":"1","key":"3550_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s12016-017-8620-9","volume":"54","author":"RM Tr\u00fceb","year":"2018","unstructured":"Tr\u00fceb RM, Dias M. Alopecia areata: a comprehensive review of pathogenesis and management. Clin Rev Allergy Immunol. 2018;54(1):68\u201387.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7","key":"3550_CR6","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s13555-023-00941-z","volume":"13","author":"N Mesinkovska","year":"2023","unstructured":"Mesinkovska N, Craiglow B, Ball SG, et al. The invisible impact of a visible disease: psychosocial impact of alopecia areata. Dermatol Ther (Heidelb). 2023;13(7):1503\u201315.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"3550_CR7","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","volume":"20","author":"N Mesinkovska","year":"2020","unstructured":"Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in alopecia areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20(1):S62\u20138.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"4","key":"3550_CR8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/jid.2013.464","volume":"134","author":"SA Mirzoyev","year":"2014","unstructured":"Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009. J Invest Dermatol. 2014;134(4):1141\u20132.","journal-title":"J Invest Dermatol"},{"key":"3550_CR9","unstructured":"Academy of Managed Care Pharmacy. Executive summary: patient input and payer decision-making. https:\/\/www.amcp.org\/sites\/default\/files\/2024-01\/ExecSummary_Patient-Input-Payer-Decision-Making.pdf. Accessed Aug 15, 2025."},{"key":"3550_CR10","unstructured":"US Food and Drug Administration. FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical. Accessed Aug 15, 2025."},{"issue":"1","key":"3550_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"F Reed Johnson","year":"2013","unstructured":"Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3\u201313.","journal-title":"Value Health"},{"key":"3550_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jdrv.2024.11.008","volume":"3","author":"AR Carmichael","year":"2025","unstructured":"Carmichael AR, Lovell KK, Prieto K, Feldman SR, Pichardo RO. Patient preferences in the treatment of alopecia areata: a review of the literature. JAAD Rev. 2025;3:21\u20135.","journal-title":"JAAD Rev"},{"issue":"2","key":"3550_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/1346-8138.17056","volume":"51","author":"T Tervonen","year":"2024","unstructured":"Tervonen T, Whichello C, Law E, et al. Treatment preferences of adults and adolescents with alopecia areata: a discrete choice experiment. J Dermatol. 2024;51(2):243\u201352.","journal-title":"J Dermatol"},{"key":"3550_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdin.2022.10.007","volume":"10","author":"JJ Han","year":"2023","unstructured":"Han JJ, Faletsky A, Ghatnekar S, et al. Factors influencing alopecia areata treatment decisions: a qualitative assessment. JAAD Int. 2023;10:77\u201383.","journal-title":"JAAD Int"},{"issue":"18","key":"3550_CR15","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O, et al. Two phase\u00a03 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"issue":"5","key":"3550_CR16","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jaad.2024.06.097","volume":"91","author":"B King","year":"2024","unstructured":"King B, Senna MM, Mesinkovska NA, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase\u00a03 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91(5):880\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"10387","key":"3550_CR17","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase\u00a02b-3 trial. Lancet. 2023;401(10387):1518\u201329.","journal-title":"Lancet"},{"key":"3550_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.097","author":"A Tsianakas","year":"2025","unstructured":"Tsianakas A, Passeron T, Magnolo N, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1\/2 inhibitor, in adults with alopecia areata: results from the THRIVE-AA2 phase\u00a03, randomized, double-blind, controlled trial. J Am Acad Dermatol. 2025. https:\/\/doi.org\/10.1016\/j.jaad.2024.06.097.","journal-title":"J Am Acad Dermatol"},{"key":"3550_CR19","unstructured":"M3 Global Research. High quality market research for the healthcare industry. https:\/\/m3globalresearch.blog\/about-m3\/. Accessed Aug 15, 2025."},{"issue":"9","key":"3550_CR20","doi-asserted-by":"publisher","first-page":"e0274772","DOI":"10.1371\/journal.pone.0274772","volume":"17","author":"ML Edwards","year":"2022","unstructured":"Edwards ML, Yin PT, Kuehn M, et al. Physician perceptions of drug utilization management: results of a national survey. PLoS One. 2022;17(9):e0274772.","journal-title":"PLoS One"},{"issue":"2","key":"3550_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1158\/1940-6207.CAPR-20-0407","volume":"14","author":"G Samimi","year":"2021","unstructured":"Samimi G, Heckman-Stoddard BM, Holmberg C, et al. Assessment of and interventions for women at high risk for breast or ovarian cancer: a survey of primary care physicians. Cancer Prev Res (Phila). 2021;14(2):205\u201314.","journal-title":"Cancer Prev Res (Phila)"},{"key":"3550_CR22","doi-asserted-by":"publisher","first-page":"569315","DOI":"10.3389\/fpubh.2021.569315","volume":"9","author":"AM Shields","year":"2021","unstructured":"Shields AM, Brown H, Phillips N, et al. Health care professionals\u2019 confidence and preferences for diagnostic assays for SARS-CoV-2: a global study. Front Public Health. 2021;9:569315.","journal-title":"Front Public Health"},{"issue":"7","key":"3550_CR23","doi-asserted-by":"publisher","first-page":"e034983","DOI":"10.1136\/bmjopen-2019-034983","volume":"10","author":"RM Zetts","year":"2020","unstructured":"Zetts RM, Stoesz A, Garcia AM, et al. Primary care physicians\u2019 attitudes and perceptions towards antibiotic resistance and outpatient antibiotic stewardship in the USA: a qualitative study. BMJ Open. 2020;10(7):e034983.","journal-title":"BMJ Open"},{"key":"3550_CR24","doi-asserted-by":"publisher","first-page":"100436","DOI":"10.1016\/j.jocm.2023.100436","volume":"49","author":"SY Assele","year":"2023","unstructured":"Assele SY, Meulders M, Vandebroek M. Sample size selection for discrete choice experiments using design features. J Choice Model. 2023;49:100436.","journal-title":"J Choice Model"},{"key":"3550_CR25","first-page":"57","volume-title":"Getting started with conjoint analysis: strategies for product design and pricing research","author":"B Orme","year":"2019","unstructured":"Orme B. Sample size issues for conjoint analysis. In: Orme B, editor. Getting started with conjoint analysis: strategies for product design and pricing research. 4th ed. Madison, WI: Research Publishers, LLC; 2019. p. 57\u201365.","edition":"4th ed"},{"key":"3550_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jdin.2022.11.010","volume":"11","author":"JJ Han","year":"2023","unstructured":"Han JJ, Manjaly P, Lee KJ, et al. Physician values in alopecia areata treatment decision-making: a qualitative assessment. JAAD Int. 2023;11:14\u201323.","journal-title":"JAAD Int"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03550-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03550-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03550-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:39:25Z","timestamp":1790609965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03550-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3550"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03550-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"James Q. Del Rosso has served as a clinical research investigator, consultant\/advisor, and\/or speaker for AbbVie, Aclaris\u00a0Therapeutics, Almirall, Amgen (Celgene), AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics, ASLAN Pharmaceuticals, Athenex, Bausch\u00a0Health (Ortho Dermatologics), Beiersdorf, Biofrontera, Biopharmix, Biorasi, BlueCreek\u00a0Pharmaceuticals, Botanix\u00a0Pharmaceuticals, Brickell\u00a0Biotech, Bristol Myers Squibb, Cara Therapeutics, Cassiopea, Dermata\u00a0Therapeutics, Dermavant Sciences, Encore, EPI Health, Evommune, Ferndale, Galderma, Genentech, Incyte, Janssen, Jem Health, La Roche-Posay,\u00a0LEO Pharma, Lilly (Dermira), MC2\u00a0Therapeutics, Nektar\u00a0Therapeutics, Novan, Nutrafol, Pfizer, Ralexar\u00a0Therapeutics, Regeneron Pharmaceuticals, Sanofi, Sente, Sol-Gel Technologies, Sonoma Pharmaceuticals\u00a0(Intraderm), Sun Pharma, UCB, Verrica Pharmaceuticals, and VYNE Therapeutics (Foamix\/Menlo); he is president of the American Acne & Rosacea Society. David Pariser is an investigator for AbbVie, Apogee Therapeutics, LEO Pharma, Lilly,\u00a0MoonLake Immunotherapeutics, Novartis, Pfizer, Priovant\u00a0Therapeutics, Regeneron Pharmaceuticals, and Veradermics, and he is on a data safety monitoring board for Bristol Myers Squibb. Neal Bhatia is an advisor, consultant, and investigator for AbbVie, Advanced Derm Solutions, Almirall, Arcutis\u00a0Biotherapeutics, Beiersdorf, Biofrontera, Boehringer Ingelheim, Botanix\u00a0Pharmaceuticals, Bristol Myers Squibb, Galderma, Johnson & Johnson, Journey, La Roche-Posay, LEO Pharma, Lilly, Novartis, Ortho\u00a0Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sagimet\u00a0Biosciences, Sanofi, Skinfix, Soligenix, Sun Pharma, and Verrica Pharmaceuticals. Kathleen L. Deering is an employee of EPI-Q and received payment from Sun Pharma associated with the development and execution of this study. Qing Harshaw was an employee of EPI-Q at the time of the study and received payment from Sun Pharma associated with the development and execution of this study. Victoria Barghout is CEO of Viver Health LLC, which receives funding from Bristol Myers Squibb, Novartis, Sun Pharma, and Taiho Pharmaceutical, and received payment from Sun Pharma associated with the development and execution of this study. Thomas J. Ferro is a former employee of Sun Pharmaceutical Industries, Inc. and a current employment of Data Loft, Inc.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and determined to be exempt by WIRB-Copernicus Group (WCG\u00ae) Institutional Review Board (protocol number 70-1059-001). Informed consent was obtained online from participants prior to study participation.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}